Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

Erika P. Hamilton, MD
Published: Sunday, Oct 08, 2017



Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Following 1 year of trastuzumab (Herceptin), patients enrolled on a clinical trial received neratinib, an oral tyrosine kinase inhibitor that blocks HER2, or placebo during another 1 year of trastuzumab, Hamilton says. This trial resulted in neratinib's FDA approval, as there was a small, but meaningful improvement (< 2%) in women who did not have their disease recur during that time.

Neratinib has been shown to have a lesser benefit in patients who have a lower risk of recurrence, she says. Another safety concern is that patients may also experience diarrhea despite taking antidiarrheal medication.


Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Following 1 year of trastuzumab (Herceptin), patients enrolled on a clinical trial received neratinib, an oral tyrosine kinase inhibitor that blocks HER2, or placebo during another 1 year of trastuzumab, Hamilton says. This trial resulted in neratinib's FDA approval, as there was a small, but meaningful improvement (< 2%) in women who did not have their disease recur during that time.

Neratinib has been shown to have a lesser benefit in patients who have a lower risk of recurrence, she says. Another safety concern is that patients may also experience diarrhea despite taking antidiarrheal medication.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x